Literature DB >> 11732900

Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases.

L F Iversen1, H S Andersen, K B Møller, O H Olsen, G H Peters, S Branner, S B Mortensen, T K Hansen, J Lau, Y Ge, D D Holsworth, M J Newman, N P Hundahl Møller.   

Abstract

Utilizing structure-based design, we have previously demonstrated that it is possible to obtain selective inhibitors of protein-tyrosine phosphatase 1B (PTP1B). A basic nitrogen was introduced into a general PTP inhibitor to form a salt bridge to Asp48 in PTP1B and simultaneously cause repulsion in PTPs containing an asparagine in the equivalent position [Iversen, L. F., et al. (2000) J. Biol. Chem. 275, 10300-10307]. Further, we have recently demonstrated that Gly259 in PTP1B forms the bottom of a gateway that allows easy access to the active site for a broad range of substrates, while bulky residues in the same position in other PTPs cause steric hindrance and reduced substrate recognition capacity [Peters, G. H., et al. (2000) J. Biol. Chem. 275, 18201-18209]. The current study was undertaken to investigate the feasibility of structure-based design, utilizing these differences in accessibility to the active site among various PTPs. We show that a general, low-molecular weight PTP inhibitor can be developed into a highly selective inhibitor for PTP1B and TC-PTP by introducing a substituent, which is designed to address the region around residues 258 and 259. Detailed enzyme kinetic analysis with a set of wild-type and mutant PTPs, X-ray protein crystallography, and molecular modeling studies confirmed that selectivity for PTP1B and TC-PTP was achieved due to steric hindrance imposed by bulky position 259 residues in other PTPs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732900     DOI: 10.1021/bi011389l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1.

Authors:  Jeyanthy Eswaran; Judit E Debreczeni; Emma Longman; Alastair J Barr; Stefan Knapp
Journal:  Protein Sci       Date:  2006-05-02       Impact factor: 6.725

2.  Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.

Authors:  Klaus Hellmuth; Stefanie Grosskopf; Ching Tung Lum; Martin Würtele; Nadine Röder; Jens Peter von Kries; Marta Rosario; Jörg Rademann; Walter Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-14       Impact factor: 11.205

Review 3.  The Gewald multicomponent reaction.

Authors:  Yijun Huang; Alexander Dömling
Journal:  Mol Divers       Date:  2010-02-27       Impact factor: 2.943

4.  Three-dimensional structure and ligand interactions of the low molecular weight protein tyrosine phosphatase from Campylobacter jejuni.

Authors:  Dmitri Tolkatchev; Rustem Shaykhutdinov; Ping Xu; Josée Plamondon; David C Watson; N Martin Young; Feng Ni
Journal:  Protein Sci       Date:  2006-10       Impact factor: 6.725

5.  Residue 182 influences the second step of protein-tyrosine phosphatase-mediated catalysis.

Authors:  Anja K Pedersen; Xiao-Ling Guo; Karin B Møller; Günther H Peters; Henrik S Andersen; Jette S Kastrup; Steen B Mortensen; Lars F Iversen; Zhong-Yin Zhang; Niels Peter H Møller
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

6.  Integrating virtual and biochemical screening for protein tyrosine phosphatase inhibitor discovery.

Authors:  Katie R Martin; Pooja Narang; José L Medina-Franco; Nathalie Meurice; Jeffrey P MacKeigan
Journal:  Methods       Date:  2013-08-20       Impact factor: 3.608

7.  A novel strategy for the development of selective active-site inhibitors of the protein tyrosine phosphatase-like proteins islet-cell antigen 512 (IA-2) and phogrin (IA-2beta).

Authors:  Paul G Drake; Günther H Peters; Henrik Sune Andersen; Wiljan Hendriks; Niels Peter H Møller
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

8.  Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.

Authors:  Dusica Vidović; Stephan C Schürer
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

9.  Suggestion of suitable animal models for in vivo studies of protein tyrosine phosphatase 1b (PTP1B) inhibitors using computational approaches.

Authors:  Xuan Thi-Anh Nguyen; Ly Le
Journal:  Springerplus       Date:  2014-07-28

10.  Druggability analysis and classification of protein tyrosine phosphatase active sites.

Authors:  Mohammad A Ghattas; Noor Raslan; Asil Sadeq; Mohammad Al Sorkhy; Noor Atatreh
Journal:  Drug Des Devel Ther       Date:  2016-09-30       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.